所有图片(1)
别名:
5-Amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione, C5 Pomalidomide, PROTAC® research ligand
经验公式（希尔记法）:
C13H11N3O4
推荐产品
ligand
thalidomide
质量水平
检测方案
≥95%
形式
powder
SMILES字符串
O=C1C2=CC=C(N)C=C2C(=O)N1C3C(=O)NC(=O)CC3
InChI
1S/C13H11N3O4/c14-6-1-2-7-8(5-6)13(20)16(12(7)19)9-3-4-10(17)15-11(9)18/h1-2,5,9H,3-4,14H2,(H,15,17,18)
InChI key
IICWMVJMJVXCLY-UHFFFAOYSA-N
应用
5-Amino-Thalidomide is a derivative of the Cereblon (CRBN)-binding ligand thalidomide. 5-Amino-Thalidomide can be used to bind the CRBN E3 ubiquitin ligase in targeted protein degradation research or in the synthesis
of protein degraders with a C5 exit vector. This was previously listed under AMBH2D6FF88F.
Related Technology Spotlight: Degrader Building Blocks for Targeted Protein Degradation
Browse our growing synthesis and research tools: Protein Degrader Building Blocks
of protein degraders with a C5 exit vector. This was previously listed under AMBH2D6FF88F.
Related Technology Spotlight: Degrader Building Blocks for Targeted Protein Degradation
Browse our growing synthesis and research tools: Protein Degrader Building Blocks
其他说明
Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1
Efficient Synthesis of Immunomodulatory Drug Analogues Enables Exploration of Structure-Degradation Relationships
Targeting the C481S Ibrutinib-Resistance Mutation in Bruton′s Tyrosine Kinase Using PROTAC-Mediated Degradation
Efficient Synthesis of Immunomodulatory Drug Analogues Enables Exploration of Structure-Degradation Relationships
Targeting the C481S Ibrutinib-Resistance Mutation in Bruton′s Tyrosine Kinase Using PROTAC-Mediated Degradation
法律信息
PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license
相关产品
产品编号
说明
价格
警示用语：
Danger
危险声明
危险分类
Acute Tox. 3 Oral - Acute Tox. 4 Dermal - Repr. 1A
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
Alexandru D Buhimschi et al.
Biochemistry, 57(26), 3564-3575 (2018-06-01)
Inhibition of Bruton's tyrosine kinase (BTK) with the irreversible inhibitor ibrutinib has emerged as a transformative treatment option for patients with chronic lymphocytic leukemia (CLL) and other B-cell malignancies, yet >80% of CLL patients develop resistance due to a cysteine
George M Burslem et al.
ChemMedChem, 13(15), 1508-1512 (2018-06-06)
The immunomodulatory drugs (IMiDs) thalidomide, pomalidomide, and lenalidomide have been approved for the treatment of multiple myeloma for many years. Recently, their use as E3 ligase recruiting elements for small-molecule-induced protein degradation has led to a resurgence in interest in
Binbin Cheng et al.
European journal of medicinal chemistry, 199, 112377-112377 (2020-05-11)
Novel resorcinol diphenyl ether-based PROTACs (PROteolysis TArgeting Chimeras) were designed and evaluated for their inhibitory activity against the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) pathway and their ability to degrade PD-L1 protein. Most of the compounds displayed excellent inhibitory
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门